The Gamma Catenin/CBP Complex Maintains Survivin Transcription in β-catenin Deficient/Depleted Cancer Cells
Keywords: Blast Crisis; Bone Marrow; CBP/p300; CREB binding protein; CREB-Binding Protein; Chromatin Immunoprecipitation assay; Imatinib; Immunoblotting; Lipofectamine Plus; accel-erated phase; acute myeloid leukemia; blast crisis; chronic myeloid; chronic myeloid leukemia; chronic myeloid leukemia (CML); erythroid; erythropoietin; granulocyte-macrophage; hematopoeisis; immunoblotted; inhibitor Imatinib; lentivirus; megakaryocytic formation; nuclear -catenin; plakoglobin; survivin; thrombopoietin; tyrosine kinase domain; β-catenin; γ-catenin
Document Type: Research Article
Publication date: 01 February 2011
- Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites